Brief: Abionyx Initiates Phase 2A Clinical Trial With CER-001 In Septic Patients

Abionyx Pharma SA

23/12/2020 06:35

Dec 23 (Reuters) - Abionyx Pharma SA  ABNX.PA :
    * ABIONYX INITIATES A PHASE 2A CLINICAL TRIAL WITH CER-001
IN
SEPTIC PATIENTS AT HIGH RISK OF DEVELOPING ACUTE KIDNEY INJURY
    * THIS PARTNERED CLINICAL STUDY WITH UNIVERSITY OF BARI AND
CBVF
FOUNDATION IS ALREADY FULLY FUNDED
    * A POTENTIALLY MODIFYING EFFECT ON PROGRESSION OF
INFLAMMATORY
CASCADE IN SEPSIS
    * PENDING POSITIVE DATA, COMPANY AIMS TO MOVE INTO PHASE 2B
BY END
OF 2021
    * TEMPORARY AUTHORIZATION FOR NAMED USE (ATUN) SHOWED
PROMISING
EFFICACY IN RENAL DISEASES
    * ENROLLMENT OF PATIENTS IN STUDY IS EXPECTED TO BEGIN IN
FIRST
HALF OF 2021

Source text for Eikon:  ID:nBwcg4PcKa 
Further company coverage:  ABNX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))